IP Verse

Methods For Treating Dlbcl - EP3412687

The patent EP3412687 was granted to Amgen Research Munich on Mar 18, 2020. The application was originally filed on Oct 27, 2011 under application number EP18164175A. The patent is currently recorded with a legal status of "Revoked".

EP3412687

AMGEN RESEARCH MUNICH
Application Number
EP18164175A
Filing Date
Oct 27, 2011
Status
Revoked
Jan 24, 2025
Grant Date
Mar 18, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEDec 18, 2020CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0623679
DESCRIPTIONWO2004106381
DESCRIPTIONWO2005052004
DESCRIPTIONWO2007068354
DESCRIPTIONWO2008119565
DESCRIPTIONWO9954440
OPPOSITIONWO2007068354

Non-Patent Literature (NPL) Citations (39) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALIZADEH et al., Nature, (20000000), vol. 403, pages 503 - 511-
DESCRIPTION- ARMITAGE, Blood, (20070000), vol. 110, no. 1, pages 29 - 36-
DESCRIPTION- Arthritis Rheum., (20060200), vol. 54, no. 2, pages 613 - 620-
DESCRIPTION- BAEK et al., Methods Enzymol., (20030000), vol. 362, pages 240 - 249-
DESCRIPTION- BERGE, S. M. et al., J. Pharm. Sci., (19770000), vol. 66, pages 1 - 19-
DESCRIPTION- Blood, (20070000), vol. 110, no. 1, pages 29 - 36-
DESCRIPTION- CHESON et al., J. Clin. Oncol., (19990400), vol. 17, no. 4, page 1244-
DESCRIPTION- CHESON et al., J. Clin. Oncol., (20070000), vol. 25, no. 5, pages 579 - 586-
DESCRIPTION- CRICK, J Mol Biol, vol. 19, (19660000), pages 548 - 555, URL: http://en.wikipedia.org/wikiA/Vobble_Hypothesis-
DESCRIPTION- DUBOIS, Arch Int Med, (19160000), vol. 17, pages 863 - 871-
DESCRIPTION- GEHAN, Cancer Chemother Rep, (19700000), vol. 54, pages 225 - 235-
DESCRIPTION- HAYCOCK, The Journal of Pediatrics, (19780000), vol. 93, no. 1, pages 62 - 66-
DESCRIPTION- MOLNAR; LAPIN; GOOTHUIS, Neurooncol., (19950000), vol. 25, no. 1, pages 19 - 28-
DESCRIPTION- MOSTELLER, N Engl J Med, (19871022), vol. 317, no. 17, page 1098-
DESCRIPTION- NEEDLEMAN; WUNSCH, J. Mol. Biol., (19700000), vol. 48, pages 443 - 453-
DESCRIPTION- NIGAVEKAR et al., Pharm Res., (20040000), vol. 21, no. 3, pages 476 - 483-
DESCRIPTION- SHIPP et al., Nat Med, (20020000), vol. 8, pages 68 - 74-
DESCRIPTION- SMITH; WATERMAN, Adv. Appl. Math, (19810000), vol. 2, pages 482 - 489-
OPPOSITION- Anonymous, "MICROMET ASH Update", Micromet Inc., (20101207), pages 1 - 28, XP055307533-
OPPOSITION- CHATENOUD et al., "Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites", Transplantation, (19910200), vol. 51, pages 334 - 338, XP055439988-
OPPOSITION- COCHLOVIUS et al., "CURE OF BURKITT'S LYMPHOMA IN SEVERE COMBINED IMMUNODEFICIENCY MICEBY T CELLS, TETRAVALENT CD3 X CD19 TANDEM DIABODY, AND CD28 COSTIMULATION", Cancer Research, (20000800), vol. 60, pages 4336 - 4341, XP001026130-
OPPOSITION- GOEBELER et al., "CD3/CD19 BISPECIFIC BITE (R) ANTIBODY BLINATUMOMAB TREATMENT OF NON-HODGKIN LYMPHOMA (NHL) PATIENTS: 60 mu G/M-2/D BY CONTINUOUS INFUSION IS TOLERABLE AND RESULTS IN DURABLE RESPONSES", Haematologica, (20100600), vol. 95, no. 2, page 230, XP002667641-
OPPOSITION- WALSH et al., "Glucocorticoids in clinical oncology", Cleveland Clinical Journal of Medicine, (19920000), vol. 59, pages 505 - 515, XP055864752-
OPPOSITION- Brandl Christian, Haas Cornelia, D’argouges Sandrine, Fisch Tanja, Kufer Peter, Brischwein Klaus, Prang Nadja, Bargou Ralf, Suzich Joann, Baeuerle Patrick A., Hofmeister Robert, "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct", Cancer Immunology, Immunotherapy, (20070220), vol. 56, no. 10, pages 1551 - 1563, XP019539092
OPPOSITION- D’argouges Sandrine, Wissing Sandra, Brandl Christian, Prang Nadja, Lutterbuese Ralf, Kozhich Alex, Suzich Joann, Locher Mathias, Kiener Peter, Kufer Peter, Hofmeister Robert, Baeuerle Patrick A., Bargou Ralf C., "Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells", Leukemia Research, (20081002), vol. 33, no. 3, pages 465 - 473, XP025894646
OPPOSITION- Molhoj; Crommer M; Brischwein S; Rau K; Sriskandarajah D; Hoffmann M; Kufer P; Hofmeister P; Baeuerle R; P A, "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis", Molecular Immunology, (20061100), vol. 44, pages 1935 - 1943, XP005792730
OPPOSITION- Dirk Nagorsen; Patrick A Baeuerle, "Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab", Experimental Cell Research, (20110316), vol. 317, pages 1255 - 1260, XP028205663
OPPOSITION- Sirohi Bhawna, Cunningham David, Norman Andy, Last Kim, Chau Ian, Horwich Alan, Oates Jacqui, Chong Geoffrey, Wotherspoon Andrew, "Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)", Hematology, (20070400), vol. 12, no. 2, pages 149 - 153, XP055982156
OPPOSITION- Marcus Robert, "Current Treatment Options in Aggressive Lymphoma", Leukemia & Lymphoma, (20030000), vol. 44, no. supplement 4, pages S15 - S27, XP055982166
OPPOSITION- Dirk Nagorsen; Ralf Bargou; Dominik Rüttinger; Peter Kufer; Patrick A Baeuerle; Gerhard Zugmaier, "Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab", Leukemia & Lymphoma, (20090600), vol. 50, no. 6, pages 886 - 891, XP008128752
OPPOSITION- Bargou R; Leo E; Zugmaier G; Klinger M; Goebeler M; Knop S; Noppeney R; Viardot A; Hess G; Schuler M; Einsele H; Brandl C; Wolf A; Kirchinger P; Klappers P; Schmidt M; Riethmuller G; Reinhardt C; Baeuerle P A; Kufer P, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", Science, (20080815), vol. 321, pages 974 - 977, XP055626096
OPPOSITION- Baeuerle Patrick A., Reinhardt Carsten, "Bispecific T-Cell Engaging Antibodies for Cancer Therapy", Cancer Research, (20090609), vol. 69, no. 12, pages 4941 - 4944, XP002665118
OPPOSITION- Cheson Bruce D., Pfistner Beate, Juweid Malik E., Gascoyne Randy D., Specht Lena, Horning Sandra J., Coiffier Bertrand, Fisher Richard I., Hagenbeek Anton, Zucca Emanuele, Rosen Steven T., Stroobants Sigrid, Lister T. Andrew, Hoppe Richard T., Dreyling Martin, Tobinai Kensei, Vose Julie M., Connors Joseph M., Federico Massimo, Diehl Volker, "Revised Response Criteria for Malignant Lymphoma", Journal of Clinical Oncology, (20070200), vol. 25, no. 5, pages 579 - 586, XP055982171
OPPOSITION- Wilson Wyndham H., Hernandez-Ilizaliturri Francisco J., Dunleavy Kieron, Little Richard F., O'connor Owen A., "Novel disease targets and management approaches for diffuse large B-cell lymphoma", Leukemia & Lymphoma, (20100727), vol. 51, no. S1, pages 1 - 10, XP008135253
SEARCH- Anonymous, "Ann Arbor staging - Wikipedia", (20170729), URL: https://en.wikipedia.org/wiki/Ann_Arbor_staging, (20180821), XP055501010 [T] 1-15 * the whole document *-
SEARCH- Matthias Klinger, "Wirkmechanismus des bispezifischen anti-CD19 x anti-CD3 BiTE-Antik?rpers MT103 in Patienten mit rezidivem indolenten B-Zell-Non-Hodgkin-Lymphom", (20090101), URL: https://publikationen.uni-tuebingen.de/xmlui/bitstream/handle/10900/43908/pdf/Dissertation_Matthias_Klinger.pdf?sequence=1&isAllowed=y, (20160713), XP055288098 [I] 1-15 * page 14, paragraph 2 * * tables 2.1,2.2,3.1 *-
SEARCH- NG ET AL, "Diffuse Large B-Cell Lymphoma", SEMINARS IN RADIATION ONCOLOGY, SAUNDERS, PHILADELPHIA, PA, US, (20070623), vol. 17, no. 3, doi:10.1016/J.SEMRADONC.2007.02.002, ISSN 1053-4296, pages 169 - 175, XP022128313 [A] 1-15 * the whole document *
SEARCH[ ] - R. BARGOU ET AL, "Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody", SCIENCE, US, (20080815), vol. 321, no. 5891, doi:10.1126/science.1158545, ISSN 0036-8075, pages 974 - 977, XP055500980 [ ] * page 1, paragraph l * * table S1 *
SEARCH- BARGOU RALF ET AL, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, (20080815), vol. 321, no. 5891, doi:10.1126/SCIENCE.1158545, ISSN 0036-8075, pages 974 - 977, XP002615656 [I] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents